Is finalized here. People don't understjd the significance and mentality of the larger PHARMA's Let the bids begin!!!!!!!!
Go back to the Yahoo zoo where logic and common sense isn't required. These pumpers are starting to bring down the neighborhood here.
303 million rev's and EU is picking up steam full force. You realize what a much more managed/capable larger Pharma would do to these sales. 2-4X Fold. I suggest you start looking for a job and make room for some real reps
Oh, I see what you mean. That explains why the company has no stalking horse bidder and why they had to extend the bidding deadline. I guess all those sophisticated big pharmas were unable to meet a deadline that has been public since October.
Uhhhh moron, you honestly think they would extent for 2 days only had they no bids. Over 40 interested party's involved and done to a handful of large and let players. Wake up, get that sour head from your a#^*
Yes, honestly. If you set a court approved deadline and then renege on it, it is grounds for any entity that submitted a timely bid to alter or withdraw that bid. No company in bankruptcy with a bona fide offer on the table would risk withdrawal of that offer to allow a potentially interested party to dither. Even Dendreon behaves rationally from time to time.
Such class and expected from a typical Yahoo pumper coming here to contaminate the board. It was so peaceful until the trash came in. Hopefully DNDN is bought out at the 296 million bid.
Hopefully so. Valeant had plenty of time to scrub the numbers so I expect it will go to closing following the confirmation hearing. Frankly I was worried that they couldn't even find a single bidder willing to pay the reserve price of $275 million, which would have been a disaster for everybody. At least this way the drug stays available to patients and some of the DNDN folks keep their job. This was probably the best outcome possible given the circumstances.
What makes you think valeant will keep anyone from dendreon? Even the sales force will be at risk. Conpany doesn't know oncology. Just desperate now. In the past they have said they have no interest in oncology (google it). They're buying the asset, will jack up the price, and milk what they can without your people.
Can't jack up the price. This is a buy-and-bill drug subject to ASP. Medicare only pays ASP+4% based upon the average selling price (including rebates) calculated from TWO quarters prior. Meaning that if you jack up the price today, the drug will be underwater on reimbursement from medicare to those buying and infusing it. This isn't a pill, folks. Or a cream. Or OTC. This is an infusible. A logistically sensitive, high overhead, customer purchased (and "at risk" of non-payment, I might add) infusible. Totally different game. If your line of thinking is how Valeant is indeed thinking, it is completely wrong. This will be a boondoggle through and through.
Anyone with oncology experience knows everything you said. What you're forgetting is nobody at valeant has oncology experience. At your first town hall ask if they know what asap stands for.
And then Valeant made their 250.000.000 USD bid dashing any hope of the penny stock. Share holders are being bent over, without the lube and the offending dick shoved in sideways.
